ALKS 📈 Alkermes - Overview

Alkermes plc is a biopharmaceutical company that focuses on developing and commercializing pharmaceutical products to address significant unmet medical needs in various therapeutic areas, including neurological disorders. The company's research and development efforts are centered in the United States, Ireland, and internationally, with a strong emphasis on creating innovative treatments for patients with limited options. Its product portfolio includes a range of proprietary commercial products, such as ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia, and VIVITROL, which is used to treat alcohol dependence and prevent opioid dependence.

The company's pipeline of clinical and preclinical product candidates is also noteworthy, with a focus on developing new treatments for neurological disorders. For instance, LYBALVI is an oral atypical antipsychotic drug candidate that has shown promise in the treatment of adults with schizophrenia and bipolar I disorder. Alkermes plc has established collaboration agreements with several major pharmaceutical companies, including Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International, to advance its research and development efforts and expand its product offerings. These partnerships have enabled the company to leverage its proprietary technology platforms and expertise to develop and commercialize new products.

Alkermes plc's business model is also built around offering its proprietary technology platforms to third-party companies, allowing them to develop, commercialize, and manufacture their own products. This approach has enabled the company to generate revenue through licensing agreements and royalties, while also advancing its mission to improve the lives of patients with serious diseases. With a history dating back to 1987, Alkermes plc has established itself as a leading player in the biopharmaceutical industry, with a strong presence in the United States, Ireland, and internationally. The company is headquartered in Dublin, Ireland, and its common stock is listed on the NASDAQ stock exchange under the ticker symbol ALKS.

From a financial perspective, Alkermes plc is classified as a common stock company, with an ISIN code of IE00B56GVS15. The company is also categorized under the GICS Sub Industry of Biotechnology, which reflects its focus on developing and commercializing innovative pharmaceutical products. With a strong portfolio of products and a pipeline of promising new candidates, Alkermes plc is well-positioned to continue making significant contributions to the field of biopharmaceuticals and improving the lives of patients around the world. For more information about the company, investors and stakeholders can visit its website at https://www.alkermes.com.